SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Managing access can be quite a daunting task in mid-to-large sized enterprises. Having a good answer for “Who should have access to what?” is not easy, to say the least. With a myriad of existing ...
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results